Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 206-218

  Antonarakis, E S ^a   Armstrong, A J ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

castrate resistant prostate cancer; clinical trials; drug development; novel therapies

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; BKM 120; CEDIRANIB; CUSTIRSEN; DASATINIB; DOCETAXEL; EVEROLIMUS; IPILIMUMAB; MITOXANTRONE; OLAPARIB; ORTERONEL; PLACEBO; PREDNISONE; RAMUCIRUMAB; RIDAFOROLIMUS; SARACATINIB; SORAFENIB; TASQUINIMOD; TEMOZOLOMIDE; TEMSIROLIMUS; TOK 001; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; ZOLEDRONIC ACID;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; FATIGUE; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT FAILURE;

EID: 80054749674     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.24     Document Type: Review

References (107)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
3. Matsunaga N, Kaku T, Ojida A, Tanaka T, Hara T, Yamaoka M et al. C(17,20)-lyase inhibitors: design, synthesis and structure- activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorg Med Chem 2004; 12: 4313-4336 (Pubitemid 39055637)
4. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid BiochemMol Biol 2010; e-pub ahead of print
5. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28 (Suppl): abstract 3084
6. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgendepleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991
7. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require fulllength androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-16765
8. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790
9. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446
10. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480-488
11. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-462
12. Sadar MD. Small molecule inhibitors targeting the Achilles heel of androgen receptor activity. Cancer Res 2011; 71: 1208-1213
13. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005; 48: 2972-2984 (Pubitemid 40552912)
14. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole- 1-yl)androsta-5, 16-diene in prostate cancer. Mol Cancer Ther 2008; 7: 2348-2357
15. Sawyers CL. New insights into the prostate cancer genome and therapeutic implications. Proceedings of the Prostate Cancer Foundation Annual Scientific Retreat, Washington, DC, 2010
16. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81 (Pubitemid 43765799)
17. Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13: 5238-5242 (Pubitemid 47510345)
18. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96: 15074-15079 (Pubitemid 30019767)
19. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-1815 (Pubitemid 46952950)
20. Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevichet E et al. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2008; 26 (Suppl): abstract 5004
21. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg Vet al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-615
22. Gerritsen W, van den Eertwegh AJ, de Gruijl T, van den Berg HP, Scheper RJ, Sackset N et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26 (Suppl): abstract 5146
23. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29-38
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
25. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175
26. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022-2029
27. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16: 1088-1093
28. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 2547-2554 (Pubitemid 30262451)
29. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-188 (Pubitemid 34137445)
30. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23: 38-46 (Pubitemid 40430679)
31. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 resensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102: 389-397 (Pubitemid 352019195)
32. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28: 4247-4254
33. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-562
34. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André Vet al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010; 16: 6150-6158
35. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-3880
36. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist 2009; 14: 667-678
37. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 2009; 124: 1-6
38. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide, a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661 (Pubitemid 40053752)
39. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189 (Pubitemid 41507982)
40. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY et al. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-3333
41. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428
42. Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1/2 study. Cancer 2011 (in press)
43. Lara Jr PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 179-184
44. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L et al. Results of a phase I trial of KX2-391, a novel non- ATP competitive substrate-pocket directed Src inhibitor, in patients with advanced malignancies. J Clin Oncol 2009; 27 (Suppl): abstract 3511
45. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormonerefractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936 (Pubitemid 32994827)
46. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714-2724 (Pubitemid 34856361)
47. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM et al. A randomized, double-blind, placebocontrolled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer: survival results of CALGB 90401. J Clin Oncol 2010; 28 (Suppl): abstract LBA4511
48. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ. Comorbidities predict overall survival in men with metastatic castrate-resistant prostate cancer. J Clin Oncol 2011 (Suppl): abstract 189
49. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM et al. A phase II clinical trial of sorafenib in androgenindependent prostate cancer. Clin Cancer Res 2008; 14: 209-214 (Pubitemid 351377997)
50. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-1640
51. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920
52. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD et al. Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-324
53. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N,Wilding G et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5166
54. Pfizer Inc. Pfizer discontinues phase 3 trial of sunitinib in advanced castration-resistant prostate cancer (press release 9/ 27/2010). http://www.pfizer.com/news/press-releases/pfizer- press-release-archive. jsp#guiddiscontinue-phase-3-trial- sutent-092710&sourceRSS-2010&page4 (accessed date 3 October 2011)
55. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer. Invest New Drugs 2007; 25: 445-451 (Pubitemid 47222908)
56. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002; 60: 1113-1117 (Pubitemid 35447590)
57. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26 (Pubitemid 40732764)
58. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67: 967-975
59. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010; 70: 10090-10100
60. Smith DC, Spira A, De Greve J, Hart H, Holbrechts S, Lin CC et al. Phase 2 study of XL184 in a cohort of patients with castration resistant prostate cancer and measurable soft tissue disease. Proceedings of the Annual EORTC Conference, Berlin, Germany, 2010, abstract 406
61. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66: 1768-1778 (Pubitemid 44893902)
62. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via their binding to quinoline carboxamides. PLoS Biol 2009; 7: e97
63. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-näve patients with metastatic castrate-resistant prostate cancer. J Clin Oncol 2010; 28 (Suppl): abstract 4510
64. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/ AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805
65. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501 (Pubitemid 37328931)
66. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2008; 6: 97-102
67. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010; 16: 3057-3066
68. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-2831 (Pubitemid 40490085)
69. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 861-871 (Pubitemid 351845217)
70. Thomas G, Speicher L, Reiter R, Ranganathan S, Hudes G, Strahs A et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Proceedings of AACR-NCIEORTC Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, 2005, abstract C131
71. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycinmediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058 (Pubitemid 41161231)
72. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508 (Pubitemid 43259931)
73. Ross RW, Manola J, Oh WK, Ryan C, Kim J, Rastarhuyeva I et al. Phase I trial of RAD001 and docetaxel in castration-resistant prostate cancer with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008; 26 (Suppl): abstract 5069
74. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a PTEN-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-7472
75. Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell5(CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): a phase II study. J Clin Oncol 2010; 28 (Suppl): abstract TPS249
76. Emmenegger U, Sridhar SS, Booth CM, Kerbel R, Berry SR, Ko Y. A phase II study of maintenance therapy with temsirolimus after response to first-line docetaxel chemotherapy in castration- resistant prostate cancer. J Clin Oncol 2010; 28 (Suppl): abstract TPS246
77. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-1432 (Pubitemid 47328700)
78. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009; 29: 1739-1743
79. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-3867 (Pubitemid 47037592)
80. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH et al. Akt activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-Myc expression. J Biol 2004; 279: 2737-2746 (Pubitemid 38114263)
81. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverŕa C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268-273
82. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083
83. Baselga J, De Jonge MJ, Rodon J, Burris HA, Birle DC, De Buck SS et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl): abstract 3003
84. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl): abstract 3005
85. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 as predictors of advanced stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106 (Pubitemid 34830730)
86. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. Increased insulin-like growth factor-1 receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620-8629 (Pubitemid 39552075)
87. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL et al. In vivo effects of the human type-1 insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-3074 (Pubitemid 40525213)
88. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P et al. An antibody targeting the type-1 insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13: 6429-6439 (Pubitemid 350075033)
89. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13: 5549-5555
90. Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K et al. A phase II study evaluating the efficacy and safety of single-agent IMC-A12, a monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5142
91. Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010; 10: 575-585
92. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103: 332-339
93. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80: 1789-1796 (Pubitemid 32012748)
94. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958-966
95. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (NCI Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115: 5541-5549
96. Rathkopf DE, Chi KN, Vaishampayan U, Hotte US, Vogelzang N, Alumkal J et al. Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer. J Clin Oncol 2009; 27 (Suppl): abstract 5064
97. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castrationresistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 181-189
98. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9: 243-257
99. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. Int J Cancer 2008; 123: 8-13 (Pubitemid 351705186)
100. Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo Vet al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 2009; 16: 401-413
101. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemo-näve castration-resistant prostate cancer. Urol Oncol 2010; e-pub ahead of print
102. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301
103. Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Curr Clin Pharmacol 2010; 5: 192-195
104. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322
105. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134
106. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737 (Pubitemid 46795129)
107. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009; 15: 7277-7290